Sodium cromoglicate
Brand names: Intal, Opticrom, Nalcrom
Sodium cromoglicate is a mast cell stabiliser used as a prophylactic agent in asthma and allergic conditions, including by ophthalmic and other topical routes.
Adult dose
Paediatric dose
Dose adjustments
No renal-impairment dosing statement is printed in the retrieved sections of this SPC.
No hepatic-impairment dosing statement is printed in the retrieved sections of this SPC.
Dose independently re-sourced from UK Summary of Product Characteristics (SPC) via MHRA Products — clinician-reviewed. Always confirm against the product SmPC and your local formulary before prescribing.
Contraindications
- Patients with known hypersensitivity to any of the ingredients listed in section 6.1
Side effects
- Transient stinging and burning on instillation of the drops
- Rarely, other symptoms of local irritation
- Benzalkonium chloride has been reported to cause eye irritation, symptoms of dry eyes and effects on the tear film and corneal surface (4.4)
- Bacterial keratitis has been reported in association with topical ophthalmic products (4.4)
Interactions
- None known (4.5)
Monitoring
- Patients should be monitored in case of prolonged use (4.4)
- Do not use while wearing soft contact lenses (benzalkonium chloride may be deposited in them): remove lenses before instillation and do not re-insert earlier than 15 minutes after use (4.4)
- Seek the physician's advice if an intercurrent ocular condition (e.g. trauma, ocular surgery or infection) develops while using the multi-dose container (4.4)
Clinical monograph
How it works
It stabilises mast cells, inhibiting the release of histamine and other inflammatory mediators triggered by allergen exposure, thereby preventing allergic and asthmatic responses.
Prescribing in practice
- It is purely prophylactic and ineffective for relief of an established acute asthma attack.
- Regular continued use is required for benefit, and it should not be stopped abruptly in those whose symptoms it controls.
- It is poorly absorbed and acts locally, so formulation must match the intended site of action.
Monitoring
Monitor symptom frequency and control to assess prophylactic benefit over time.
Counselling the patient
- Use regularly to prevent symptoms rather than to treat an attack.
- Continue even when well, and keep a reliever for acute symptoms if you have asthma.
Evidence & guidelines
Mast cell stabilisers have a long-established prophylactic role in allergic and asthmatic disease.
Reference: BTS/SIGN; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. The structured dose values shown have been reviewed by a clinician. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Corrected Sodium (Hyperglycaemia) · Electrolytes
- Random C-Peptide — Diabetes Classification · Diabetes Classification
- Hyponatraemia Cause Algorithm · Electrolyte Disorders
- IMDC (Heng) Score for Metastatic RCC · Renal Cell Carcinoma
- MELD-Na Score · Liver Disease
- MELD-Na Score for Liver Cirrhosis · Hepatology
- Acute Asthma in Adults · BTS/SIGN British Guideline on Asthma 2019; NICE NG80
- Pulmonary Embolism Assessment · NICE NG158; ESC 2019 PE Guidelines
- Acute Exacerbation of COPD (AECOPD) · NICE NG115; GOLD 2024
- Spontaneous Pneumothorax (Adult) · BTS Pleural Disease 2023
- Atypical Pneumonia (Legionella / Mycoplasma / Chlamydophila) · BTS 2023; IDSA
- COPD Exacerbation Management · NICE NG115 / GOLD 2024